Japan should fundamentally overhaul its cost-effectiveness assessment (CEA) scheme while putting a hold on CEA-based price adjustments, a new ruling…
HOME > REGULATORY
REGULATORY
- LDP Legislators Discuss Legal Regulation of Clinical Research
April 1, 2015
- MHLW to Invite Candidate Products for “Sakigake” Designation System
March 31, 2015
- MHLW Reiterates Caution on Skin Disorders for Lamictal: Safety Bulletin
March 31, 2015
- Otani, Ex-Number 2 at MHLW, Tapped as Aide to Chief of AMED
March 30, 2015
- PMDA Launches Consultation Services for Academia-Led Trials
March 30, 2015
- MHLW OKs 32 Products Including Sovaldi, Lenvima
March 27, 2015
- Nonpartisan Group Launched to Push Biosimilar Use, Lawmaker-Sponsored Bill Eyed
March 27, 2015
- Govt OKs AMED’s 5-Year Plan Articulating Support for 200 Drug Seed Development Projects
March 26, 2015
- Cabinet OKs NIBIO Director Yoneda as Chief of Merged Institute
March 25, 2015
- Ministry Requires Addition of Thrombocytopenia as Serious ADR to Januvia
March 25, 2015
- Lawmakers to Form Nonpartisan Group to Spur Biosimilar Use
March 24, 2015
- Kitasato Daiichi Sankyo Vaccine to Remain in State Vaccine Project
March 24, 2015
- PMDA Pledges Cooperation to Promote Commercialization of Seeds: Chief Executive
March 24, 2015
- Editor’s Pick: Five Healthcare News Headlines for March 9 - 22
March 23, 2015
- MHLW OKs Pfizer’s Jzoloft for PTSD Indication, Other Drugs
March 23, 2015
- 196 “Designated Intractable Diseases” Likely to Be Eligible for Subsidies from July
March 20, 2015
- Physicians Becoming Picky about Generic Brands: Survey
March 19, 2015
- Chuikyo OKs Quantitative Premium Calculation for Operating Profit Rates
March 19, 2015
- Japan to Build Dementia Patients Registration System: WHO Ministerial Conference
March 19, 2015
- Chuikyo Approves Reimbursement for RAS Gene Test Kit; Listing Scheduled for April
March 19, 2015
ページ
Global drug makers are forging ahead with therapies targeting lipoprotein(a), or Lp(a), a promising new approach to reducing cardiovascular risks.…
Japanese Prime Minister Sanae Takaichi said on October 14 that the government will consider the necessary measures for the FY2027…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…